Physician profile
Suber Huang
NPI 1598781395
$123,729.41
in general payments reported to CMS, 2019-2025
18 companies · $6,428 in 2025
The $6,428 reported for 2025 was more than what 88% of Retina Specialist providers received nationally (typical 2025 total: $460).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,509 · 2020: $2,964 · 2021: $4,521 · 2022: $1,563 · 2023: $1,029 · 2024: $101K · 2025: $6,428.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $100K · Acquisitions: $6,317 · Consulting Fee: $1,200 · Food and Beverage: $656.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $100,000.00 |
| Acquisitions | $6,316.78 |
| Consulting Fee | $1,200.00 |
| Food and Beverage | $656.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $100,026.19 | 2024-2025 | Xipere |
| Cortigent INC | $12,600.00 | 2019-2024 | Orion Visual Cortical Prosthesis |
| Alcon Vision LLC | $6,316.78 | 2025 | |
| Nidek Co., LTD. | $2,000.00 | 2021 | |
| Novo Nordisk As | $1,515.84 | 2019 | |
| Apellis Pharmaceuticals, INC. | $336.29 | 2022-2025 | Syfovre |
| Allergan, INC. | $182.94 | 2019-2021 | |
| Dutch Ophthalmic, USA | $171.51 | 2023 | Eva, Combined Machine, Tissueblue |
| Regeneron Healthcare Solutions, INC. | $139.43 | 2020-2024 | Eylea |
| Alimera Sciences, INC. | $111.31 | 2019-2022 | |
| Genentech USA, INC. | $89.14 | 2021-2025 | Vabysmo, Susvimo |
| Astellas Pharma US INC | $74.82 | 2023-2024 | Izervay |
| Regeneron Pharmaceuticals, INC. | $57.46 | 2023 | Eylea Hd |
| Genentech, INC. | $30.04 | 2023 | Vabysmo |
| Eyepoint US, INC. | $25.59 | 2021 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coherus Oncology, INC. | $23.52 | 2023 | |
| Novartis Pharmaceuticals Corporation | $16.56 | 2019 | |
| Spark Therapeutics, INC. | $11.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suber Huang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.